Onconova Therapeutics Operating Income

Onconova Therapeutics (ONTX) currently reports a operating income of $-7B as of March 2026. That compares with $-37M in the prior-year period — down 18769.0% year over year. Use the charts on this page to explore Onconova Therapeutics's operating income history and peer comparisons.

Onconova Therapeutics's operating income decreased from $-37M to $-7B — a 18769.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Onconova Therapeutics reported $-7B in operating income as of March 2026. That compares with $-37M in the prior-year period — down 18769.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-7B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Onconova Therapeutics, and consider following ONTX for alerts when major investors trade the stock.

Onconova Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-7B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ONTX with unrelated industries.